
DMRA Stock Forecast & Price Target
DMRA Analyst Ratings
Bulls say
Damora Therapeutics is entering a critical phase in medical development with their pipeline products showing compatibility and strong response with existing benchmarks and clearing a top competitor for Type 2 activity. Despite being priced at an apparent premium to their established value of $750M and anti-carcinogenic line aimed at first gen efficacy-above convenience line, existing cash reserve and demonstrated target validation presents a compelling investment opportunity as their expected mid-2027 proof-of-concept study and subQ biologics pose significant upside.
Bears say
Damora Therapeutics is a biotechnology company with a strong pipeline of potential treatments for hematologic disorders, including DMR-001, DMR-002, DMR-003, and GB3226. Despite promising preclinical data for DMR-001 and a potential market in both essential thrombocythemia (ET) and myelofibrosis (MF), there are concerns about the company's ability to effectively penetrate the market and maintain a competitive advantage. Additionally, the need for repeat dosing of DMR-001 and the potential for immunogenicity could negatively impact commercial viability and market access.
This aggregate rating is based on analysts' research of Damora Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
DMRA Analyst Forecast & Price Prediction
Start investing in DMRA
Order type
Buy in
Order amount
Est. shares
0 shares